mProX™ Human RET Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;LNCap

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research

Related Diseases

Hirschsprung Disease 1; Multiple Endocrine Neoplasia, Type Iia

Gene ID

Human:5979

UniProt ID

Human:P07949

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RET (rearranged during transfection) is a gene that encodes a receptor tyrosine kinase involved in various cellular processes. It has been found to be implicated in several diseases, including histiocytic neoplasms, differentiated thyroid cancer, and papillary thyroid carcinoma. In histiocytic neoplasms, activating alterations in RET, along with other genes such as ALK and CSF1R, have shown anecdotal evidence of successful targeted treatment. In pediatric thyroid tumors and differentiated thyroid cancer, fusions involving the RET gene, as well as other genetic alterations like ALK and BRAF, have been identified. In papillary thyroid carcinoma, a long non-coding RNA called PFAR has been found to facilitate tumor proliferation and migration by mediating the miR-15a/RET axis. Additionally, the RET inhibitor selpercatinib has shown promise in treating RET-mutated medullary thyroid cancer and RET fusion-positive non-small cell lung cancer. These findings highlight the importance of tumor sequencing and personalized treatment approaches in targeting RET alterations in various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human RET Stable Cell Line (S01YF-1023-PY85). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Brown (Verified Customer)

What is the role of RET in cancer and how are RET inhibitors used in therapy? Apr 01 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

RET is a receptor tyrosine kinase involved in various cancers, and selective RET inhibitors like pralsetinib and selpercatinib have shown efficacy in treating RET fusion-positive tumors, including lung and thyroid cancers. Apr 01 2022

chat Skyler Johnson (Verified Customer)

How does RET gene alteration affect cancer prognosis? Mar 29 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Alterations in the RET gene can significantly impact the progression and prognosis of certain cancers, making it a critical target in precision oncology. Mar 29 2021

Published Data

Fig.1 A decrease in tumor growth in vivo is observed following the knockdown of RET.

Subcutaneous inoculation of SCID mice was performed using LNCaP cells with RET knockdown (si-RET) or vector control cells (si-V), and tumor growth was monitored over a period of 5 weeks, during which tumor volumes were subsequently calculated.

Ref: Ban, Kechen, et al. "RET signaling in prostate cancer." Clinical Cancer Research 23.16 (2017): 4885-4896.

Pubmed: 28490466

DOI: 10.1158/1078-0432.CCR-17-0528

Research Highlights

Zhou, Caicun. et al. "First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC" The New England journal of medicine, 2023.
Sel***nib, a potent and selective RET inhibitor with strong brain penetration capabilities, has demonstrated successful outcomes in patients with advanced disease. This study evaluated the efficacy of selpercatinib in this patient population. Results showed significant improvements in disease progression, with manageable side effects reported. Further clinical trials are warranted to confirm these findings and assess long-term outcomes. This highlights the potential therapeutic role of selpercatinib in patients with advanced disease. Overall, selpercatinib shows promising benefits for targeted treatment in this population.
Zhou, Caicun. et al. "First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC" The New England journal of medicine, 2023.
Pubmed: 37870973 DOI: 10.1056/NEJMoa2309457

Hadoux, Julien. et al. "Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer " The New England journal of medicine, 2023.
Se*p*in*b, a potent and highly selective inhibitor of the RET protein, has demonstrated effectiveness in the treatment of advanced non-small cell lung cancer. This orally administered medication targets and blocks the activity of RET, a protein that has been linked to the progression and proliferation of cancer cells. In clinical trials, selpercatinib has shown promising results and may offer a new treatment option for individuals with this type of cancer.
Hadoux, Julien. et al. "Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer " The New England journal of medicine, 2023.
Pubmed: 37870969 DOI: 10.1056/NEJMoa2309719